Sun Pharma announces US nod for Topamax tablets

Drug firm Sun Pharmaceutical Industries today said the US health regulator, the Food and Drug Administration, has approved its Abbreviated New Drug Application (ANDA) to market generic Topamax, topiramate tablets used in treatment of partial onset seizures.

Topiramate tablets are the generic version of Topamax tablets from the Ortho-McNeil Janssen Pharmaceuticals portfolio and are available in four strengths, 25 mg, 50 mg, 100 mg and 200 mg, the company has said. These strengths of Topamax tablets have annual sales of approximately $2.5 billion in the US, it added.